Volume 17, Number 6—June 2011
Dispatch
Outcome Predictors in Treatment of Yaws
Oriol Mitjà
, Russell Hays, Anthony Ipai, David Gubaila, Francis Lelngei, Martin Kirara, Raymond Paru, and Quique Bassat
, Russell Hays, Anthony Ipai, David Gubaila, Francis Lelngei, Martin Kirara, Raymond Paru, and Quique Bassat
Table 1
Demographic data, clinical signs/symptoms, laboratory results, and outcome after treatment of yaws in 138 case-patients, Papua New Guinea, January–September, 2009*
| Characteristic | Total no. (%) patients, N = 138 |
|---|---|
| Mean age, y (SD) | 9.6 (4.4) |
| Male sex |
81 (58.7) |
| VDRL titer | |
| 16 | 54 (39.1) |
| 32 | 33 (23.9) |
| 64 | 42 (30.4) |
| 128 |
9 (6.5) |
| Primary skin lesion | 81 (58.7) |
| Secondary stage |
63 (45.7)† |
| Family history |
36 (26.1) |
| Treatment with IM penicillin G benzathine | 138 (100.0) |
| Clinical healing | 132 (95.7) |
| Concurrent disease | 7 (5.1)‡ |
| Seroconversion | 63 (45.7) |
| Serologically defined treatment failure | 24 (17.4) |
*VDRL, Venereal Disease Research Laboratory; IM, intramuscular.
†Includes 7 cases of early yaws osteoperiostitis, among whom were 3 patients with dactylilitis.
‡Includes 3 cases of Plasmodium falciparum malaria, 1 case of P. vivax malaria, 1 case of acute diarrhea diagnosed at the 12-month follow-up visit, and 2 case-patients with a chronic underlying disease (1 case of congenital heart disease and 1 case of chronic asthma).
Page created: September 01, 2011
Page updated: September 01, 2011
Page reviewed: September 01, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.